Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2005
03/30/2005EP1345944B1 Process for the isolation and purification of epothilones
03/30/2005EP1322350B1 E-ptfe foil impregnated with an encapsulated bioactive substance
03/30/2005EP1250093B1 Method for preventing fluorescence quenching
03/30/2005EP1124570A4 Novel neuropilin/growth factor binding and uses thereof
03/30/2005EP1105378B1 Quinazoline derivatives
03/30/2005EP1091942B1 Potassium channel blocking agents
03/30/2005EP1076561B1 Combination therapy for the treatment of tumors
03/30/2005EP0804194B1 Use of retinoic acid receptor-agonists or ap-1 antagonists for the manufacture of a medicament for preventing proliferation of retinal pigment epithelium
03/30/2005EP0791056B1 Lipid-cleavage enzyme complex
03/30/2005CN1602355A Human fibroblast growth factor-related compositions
03/30/2005CN1602317A Angiopoietin-2 specific binding agents
03/30/2005CN1602315A Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
03/30/2005CN1602311A Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible NO-synthase
03/30/2005CN1602307A Substituted 6h-dibenzo[c, h]chromenes as estrogenic agents
03/30/2005CN1602302A Biscyanophenylmethyl-triazole for use in prevention of breast cancer
03/30/2005CN1602199A Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
03/30/2005CN1602195A Quinazoline derivatives for the treatment of abnormal cell growth
03/30/2005CN1602192A Compositions comprising epothilones and their use for the treatment of carcinoid syndrome
03/30/2005CN1602191A Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
03/30/2005CN1602187A Valdecoxib-based composition prepared by spray drying process and exhibiting rapid oral dissolution
03/30/2005CN1600857A RIP5 gene and usage
03/30/2005CN1600792A Active material of polypeptide proteins in bloody clam, preparation method and usage
03/30/2005CN1600788A Distinguishing gene for adjusting and controlling anti-oncogene p53 and usage
03/30/2005CN1600783A Imidazopyridine derivatives
03/30/2005CN1600330A Application of Chinese magnoliaving and its extractive on curing drug resistance for multiple drugs of treating tumors
03/30/2005CN1600317A Low polarity ginsenoside combination possessing anti-tumor activity
03/30/2005CN1600307A Control releasing administration system for temozolomide
03/30/2005CN1600298A Application of Schizandrin A on curing drug resistance for multiple drugs of treating tumors
03/30/2005CN1195056C Recombined virus for specific proliferation and high efficiency expression of anti-cancer gene in tumor cells and its constitution method
03/30/2005CN1194979C Medical radioactive rhenium-aminophosphonic acid compound and preparing process thereof
03/30/2005CN1194978C Phosphinous and phosphonic acid derivs. used as medicaments
03/30/2005CN1194976C Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
03/30/2005CN1194764C Use of radium-223 in preparing medicine for treating bone affected diseases
03/30/2005CN1194757C Medical health oral liquid and its prepn
03/30/2005CN1194692C Method of inhibiting skin damage of vitamin A analog
03/30/2005CN1194680C Anticancer nutritive Chinese medicine
03/29/2005US6872852 Polyamine analogues as cytotoxic agents
03/29/2005US6872851 Melatonergic receptors; antiinflammatory agents; anticancer agents
03/29/2005US6872838 Derivatives of water insoluble drugs which exhibit good activity and water solubility
03/29/2005US6872837 Taxanes having a c10 Heterosubstituted acetate substituent
03/29/2005US6872750 Modulating angiogenesis
03/29/2005US6872747 Decalactones, method for making, and pharmaceuticals there from
03/29/2005US6872746 Isomeric fused pyrrolocarbazoles and isoindolones
03/29/2005US6872738 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
03/29/2005US6872737 Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis
03/29/2005US6872730 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
03/29/2005US6872728 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
03/29/2005US6872714 Methods to modulate conditions mediated by the CXCR4 receptor
03/29/2005US6872712 Cyclic glycerophosphates and analogs thereof
03/29/2005US6872702 Cyclic peptide; antitumor agents; antiinflammatory agents; tissue remodeling
03/29/2005US6872700 Methods for glucagon suppression
03/29/2005US6872528 Cell culture; for use as tool in gene therapy and cel packaging
03/29/2005US6872393 Polyalkylene oxide-modified single chain polypeptides
03/29/2005US6872392 Humanized antibodies
03/29/2005US6872385 Adjuvant preparation for the induction of specific immunity
03/29/2005CA2425745C Expression of exogenous polynucleotide sequences in a vertebrate
03/29/2005CA2335186C Pyrrolo[2,3-d]pyrimidine compounds
03/29/2005CA2280447C Pyrrolo¬1,2-a|pyrazine derivatives as 5ht1a ligands
03/29/2005CA2268870C Heterocyclic carboxamides
03/29/2005CA2049287C Expression of exogenous polynucleotide sequences in a vertebrate
03/26/2005CA2441695A1 Regulation of matrix metalloproteinases by psp94 family members
03/24/2005WO2005026741A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
03/24/2005WO2005026728A1 Screening method
03/24/2005WO2005026357A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells
03/24/2005WO2005026355A1 Method of evaluating cancerization degree
03/24/2005WO2005026354A1 Method of evaluating cancerization degree
03/24/2005WO2005026353A1 Method of evaluating cancerization degree
03/24/2005WO2005026352A1 Method of evaluating cancerization degree
03/24/2005WO2005026351A1 Method of evaluating cancerization degree
03/24/2005WO2005026350A1 Method of evaluating cancerization degree
03/24/2005WO2005026337A2 Adenoviral vector for infecting cells deficient in a car receptor
03/24/2005WO2005026185A1 Novel indolopyrrolocarbazole derivative with antitumor activity
03/24/2005WO2005026170A2 Uses of neuronal pannexins for therapy and diagnosis in mammals
03/24/2005WO2005026169A1 Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof
03/24/2005WO2005026157A1 Quinazoline derivatives
03/24/2005WO2005026156A1 Quinazoline derivatives
03/24/2005WO2005026152A1 Quinazoline derivatives as antitumor agents
03/24/2005WO2005026151A1 Quinazoline derivatives as tyrosine kinase inhibitors
03/24/2005WO2005026150A1 Quinazoline derivatives as tyrosine kinase inhibitors
03/24/2005WO2005026127A1 Plasminogen activator inhibitor-1 inhibitor
03/24/2005WO2005025620A2 Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
03/24/2005WO2005025619A1 Combination of a histone deacetylase inhibitor with a death receptor ligand
03/24/2005WO2005025610A1 Use of markk or markk antagonists for the treatment of pathologies characterised by increased or reduced phosphorylation of mark or tau protein
03/24/2005WO2005025600A1 Drug inhibiting mobilization of adhesive cells into peripheral blood
03/24/2005WO2005025598A1 Antibacterial drug for propionibacterium acnes
03/24/2005WO2005025596A1 Glatiramer acetate for use as an immuno-modulatory agent
03/24/2005WO2005025581A1 Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
03/24/2005WO2005025574A2 PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES.
03/24/2005WO2005025569A1 Use of known active ingredients as radical scavengers
03/24/2005WO2005025557A1 An agent for plasminogen-activation and matrix metalloproteinase associated conditions and methods of use
03/24/2005WO2005025552A2 Protein binding compounds
03/24/2005WO2005025494A2 Vaccine immunotherapy for immune suppressed patients
03/24/2005WO2005019220A3 Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
03/24/2005WO2005009967A3 Quinolinone derivatives as inhibitors of c-fms kinase
03/24/2005WO2005009348A3 Substituted purine derivatives
03/24/2005WO2005007653A3 Substituted tetrahydro-1h-pyrazolo[3,4-c]pyridines, compositions containing same and use
03/24/2005WO2005005389A3 Malonamide derivatives
03/24/2005WO2005004942A3 Injectable composite for the magnetocytolysis of bone metastatic cells
03/24/2005WO2005000348A3 Vaccines inducing nkt-cell and toll-like-receptor activation
03/24/2005WO2005000332A3 Therapeutic agent for soft tissue sarcoma
1 ... 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 ... 2211